NCT06906822
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06906822
Title PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients (PlugIN)
Acronym PlugIN
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Espanol Multidisciplinar de Melanoma
Indications
Therapies
Age Groups: senior | adult
Covered Countries ESP


No variant requirements are available.